Leukemia is a highly aggressive hematological malignancy characterized by extensive molecular changes that affect clinical outcomes and provide potential drug development targets. However, the emergence of chemotherapy resistance obviously hinders the effect of chemotherapy and indicates a poor prognosis. About 15% – 30% of leukemia patients are resistant to chemotherapy, and 60% – 80% of patients with complete remission inevitably relapse and succumb to the disease. Therefore, it is very…